2,2-dimethyl-3-tridecanone | 86788-12-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-dimethyl-3-tridecanone
• 英文别名: 2,2-dimethyltridecan-3-one
• CAS: 86788-12-7
• 化学式: C₁₅H₃₀O
• 分子量: 226.403
• InChiKey: WQUGTNLJWGTNHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (E)-3,4-bis(ethenyl)hept-5-enenitrile 在 硫酸 作用下， 生成 2,2-dimethyl-3-tridecanone
  参考文献：
  名称：

  An enolate-accelerated cope rearrangement

  摘要：

  DOI：

  10.1016/s0040-4039(00)98723-9

文献信息

• Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135385A1

  公开（公告）日：2007-06-14

  Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.

  吲哚和与吲哚相关的化合物、组合物以及方法被披露。发明中的这些化合物作为磷脂酶抑制剂非常有用。发明中的这些化合物和组合物用于治疗动物受试者中的磷脂酶相关状况，例如胰岛素相关、体重相关和/或胆固醇相关状况。
• NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS
  申请人：MetCalf, III Chester A.

  公开号：US20100184649A1

  公开（公告）日：2010-07-22

  The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against Clostridium difficile.

  本发明涉及新型脂肽化合物，这些化合物的药物组合物以及使用这些化合物作为抗菌化合物的方法。本发明的化合物特别适用于对抗各种细菌，包括耐药菌株。这些化合物可用作抗Clostridium difficile的抗菌剂。
• INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS
  申请人：Chang Han-Ting

  公开号：US20090318492A1

  公开（公告）日：2009-12-24

  Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.

  本发明揭示了吲哚及其相关化合物、组合物和方法。本发明的化合物可用作磷脂酶抑制剂。本发明的化合物和组合物可用于治疗与磷脂酶相关的疾病，如动物主体中与胰岛素、体重和/或胆固醇相关的疾病。
• AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS
  申请人：Chang Han-Ting

  公开号：US20090239896A1

  公开（公告）日：2009-09-24

  Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. The compounds include azaindoles of the formula below [insert FIG. 6 c ] in which at least one of CR4, CR5, CR6 and CR7 is replaced by N, and the groups R1-R7 are defined as in claim 1.

  本发明涉及吲哚及其相关化合物、组合物和方法。本发明的化合物可用作磷脂酶抑制剂。本发明的化合物和组合物可用于治疗磷脂酶相关疾病，例如动物主体中的胰岛素相关、体重相关和/或胆固醇相关疾病。化合物包括以下式子中的氮杂吲哚[插入FIG.6c]，其中CR4、CR5、CR6和CR7中的至少一个被N替换，且R1-R7基团如权利要求1所定义。
• Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135383A1

  公开（公告）日：2007-06-14

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

  本发明提供了治疗磷脂酶相关疾病的方法和组合物。具体地，本发明提供了一种用于治疗动物主体中的胰岛素相关、体重相关和/或胆固醇相关疾病的方法。该方法通常涉及在胃肠道腔中定位的非吸收和/或外流的磷脂酶A2抑制剂的给药。